{"id":"https://openalex.org/W1991907429","doi":"https://doi.org/10.1038/clpt.2012.244","title":"Physiologically Based Pharmacokinetic Models of Tyrosine Kinase Inhibitors: A Systems Pharmacological Approach to Drug Disposition","display_name":"Physiologically Based Pharmacokinetic Models of Tyrosine Kinase Inhibitors: A Systems Pharmacological Approach to Drug Disposition","publication_year":2012,"publication_date":"2012-12-18","ids":{"openalex":"https://openalex.org/W1991907429","doi":"https://doi.org/10.1038/clpt.2012.244","mag":"1991907429","pmid":"https://pubmed.ncbi.nlm.nih.gov/23340476"},"language":"en","primary_location":{"id":"doi:10.1038/clpt.2012.244","doi":"https://doi.org/10.1038/clpt.2012.244","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2012.244","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056500955","display_name":"James M. Gallo","orcid":"https://orcid.org/0000-0003-1553-4817","observed_orcids":["https://orcid.org/0000-0003-1553-4817"]},"institutions":[{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J M Gallo","raw_affiliation_strings":["Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, USA. james.gallo@mssm.edu","Department of Pharmacology and Systems Therapeutics Mount Sinai School of Medicine New York New York USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York, USA. james.gallo@mssm.edu","institution_ids":["https://openalex.org/I98704320"]},{"raw_affiliation_string":"Department of Pharmacology and Systems Therapeutics Mount Sinai School of Medicine New York New York USA","institution_ids":["https://openalex.org/I98704320"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5056500955"],"corresponding_institution_ids":["https://openalex.org/I98704320"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":0.668,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.62731106,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"93","issue":"3","first_page":"236","last_page":"238"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.3522999882698059,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.3522999882698059,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.2011999934911728,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.16699999570846558,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":1.0},{"id":"https://openalex.org/keywords/physiologically-based-pharmacokinetic-model","display_name":"physiologically based pharmacokinetic modeling","score":0.9929999709129333},{"id":"https://openalex.org/keywords/drug-disposition","display_name":"drug disposition","score":0.6399999856948853},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.7480000257492065},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7170000076293945},{"id":"https://openalex.org/keywords/anticancer-drug-therapy","display_name":"cancer drug therapy","score":0.7929999828338623},{"id":"https://openalex.org/keywords/systems-pharmacology","display_name":"systems pharmacology","score":0.718999981880188}],"concepts":[{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.7979187369346619},{"id":"https://openalex.org/C185867374","wikidata":"https://www.wikidata.org/wiki/Q2562769","display_name":"Physiologically based pharmacokinetic modelling","level":3,"score":0.7686368823051453},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7595064640045166},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7364073991775513},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.690407395362854},{"id":"https://openalex.org/C38022665","wikidata":"https://www.wikidata.org/wiki/Q1149305","display_name":"Disposition","level":2,"score":0.6845301389694214},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5971683859825134},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5298694968223572},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4583962857723236},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44739121198654175},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.10659846663475037},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.10174807906150818},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1000189483165741},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0950160026550293},{"id":"https://openalex.org/C77805123","wikidata":"https://www.wikidata.org/wiki/Q161272","display_name":"Social psychology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D057285","descriptor_name":"Precision Medicine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1038/clpt.2012.244","doi":"https://doi.org/10.1038/clpt.2012.244","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2012.244","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:23340476","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23340476","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5201238762","display_name":null,"funder_award_id":"CA073728","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G7349805395","display_name":"Interactions Between Cytotoxic and Antiangiogenic Drugs","funder_award_id":"R01CA072937","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8999998882","display_name":"Development of Targeted Anticancer Drugs","funder_award_id":"R01CA127963","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320306631","display_name":"National Brain Tumor Society","ror":"https://ror.org/051687e73"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1963558982","https://openalex.org/W2012332584","https://openalex.org/W2109477330","https://openalex.org/W2140204532","https://openalex.org/W2150575159"],"related_works":["https://openalex.org/W2348282417","https://openalex.org/W2529080015","https://openalex.org/W4399535450","https://openalex.org/W4388223083","https://openalex.org/W132218999","https://openalex.org/W2012978969","https://openalex.org/W4398256225","https://openalex.org/W7151101523","https://openalex.org/W4408026600","https://openalex.org/W15965576"],"abstract_inverted_index":{"The":[0],"emergence":[1],"of":[2,42,46,67,70],"low-molecular-weight":[3],"tyrosine":[4],"kinase":[5],"inhibitors":[6],"(TKIs)":[7],"has":[8,35],"revolutionized":[9],"anticancer":[10],"drug":[11,47],"therapy.":[12],"It":[13],"is":[14],"not":[15],"unexpected":[16],"that":[17],"lead":[18],"TKIs":[19],"are":[20],"sought":[21],"with":[22],"favorable":[23],"macropharmacokinetic":[24],"characteristics,":[25],"such":[26],"as":[27],"high":[28],"oral":[29],"bioavailability;":[30],"however,":[31],"surprisingly":[32],"little":[33],"emphasis":[34],"been":[36],"given":[37],"to":[38],"the":[39,44,68],"tissue":[40],"disposition":[41],"TKIs,":[43],"site":[45],"action.":[48],"This":[49],"article":[50],"discusses":[51],"how":[52],"physiologically":[53],"based":[54],"pharmacokinetic":[55],"(PBPK)":[56],"models":[57],"can":[58],"address":[59],"this":[60],"deficiency":[61],"and":[62],"help":[63],"improve":[64],"our":[65],"understanding":[66],"determinants":[69],"TKI":[71],"efficacy.":[72],"Clinical":[73],"Pharmacology":[74],"&":[75],"Therapeutics":[76],"(2013);":[77],"93":[78],"3,":[79],"236\u2013238.":[80],"doi:10.1038/clpt.2012.244":[81]},"counts_by_year":[{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}